| Literature DB >> 35351001 |
Ryuta Muraki1, Yoshifumi Morita2, Shinya Ida1, Ryo Kitajima1, Satoru Furuhashi1, Makoto Takeda1, Hirotoshi Kikuchi1, Yoshihiro Hiramatsu1,3, Atsuko Fukazawa4, Takanori Sakaguchi4, Mayu Fukushima5, Eisaku Okada6, Hiroya Takeuchi1.
Abstract
BACKGROUND: Various hemostatic devices have been utilized to reduce blood loss during hepatectomy. Nonetheless, a comparison between monopolar and bipolar coagulation, particularly their usefulness or inferiority, has been poorly documented. The aim of this study is to reveal the characteristics of these hemostatic devices.Entities:
Keywords: Ascites; Hemostatic device; Hepatectomy; Intra-abdominal infection; Propensity score matching
Mesh:
Year: 2022 PMID: 35351001 PMCID: PMC8962169 DOI: 10.1186/s12876-022-02231-y
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Fig. 1Hemostatic devices. During coagulation of the liver parenchyma, saline is dripped through the electrode tip to prevent the adherence of clots. The end of the tube is connected to a saline bottle for drip infusion. a monopolar device, b bipolar device
Fig. 2Flow diagram for the study. CUSA, Cavitron Ultrasonic Surgical Aspirator; PSM, propensity score matching
Patient characteristics before propensity score matching
| Monopolar (n = 160) | Bipolar (n = 104) | ||
|---|---|---|---|
| Age | 68 (17–87, 14) | 69 (30–85, 13) | 0.745 |
| Sex (male/female) | 116/44 | 73/31 | 0.685 |
| BMI | 22.7 (12.5–32.3, 4.50) | 22.7 (15.9–37.1, 4.40) | 1.000 |
| ASA (1/2/3) | 14/130/16 | 10/79/15 | 0.516 |
| Diagnosis (HCC/CCC/meta/biliary tract cancer/benign disease/other) | 72/10/42/16/17/3 | 65/6/21/3/9/0 | |
| Background liver disease (normal/HCV/HBV/ASH/NASH/other) | 90/43/12/4/8/3 | 42/43/9/3/5/2 | 0.135 |
| Liver fibrosisa (f0–1, f2–4) | 57/56 | 33/51 | 0.120 |
| Type of resection (partial/lateral/subsegmentectomy/segmentectomy/hemihepatectectomy/trisegmentectomy) | 48/2/38/22/48/2 | 22/5/33/14/30/0 | 0.362 |
| Number of resected lesions | 1 (1–16, 0) | 1 (1–3, 0) | 0.970 |
| Size of the largest nodule on preoperative imagingb (cm) | 2.5 (0.60–20, 3.0) | 2.5 (0.50–13, 2.0) | 0.776 |
| Number of nodules on preoperative imagingb | 1 (1–10, 1) | 1 (1–10, 1) | 0.868 |
| Lymph node dissection (yes/no) | 37/123 | 11/93 | |
| Biliary reconstruction (yes/no) | 24/136 | 7/97 | |
| Intraoperative drain insert (yes/no) | 159/1 | 104/0 | 0.606 |
| Duration of drain placement | 5 (0–223, 5) | 5 (2–94, 3) | 0.272 |
| Neoadjuvant chemotherapy (yes/no/previous) | 27/120/13 | 11/90/3 | 0.059 |
| Total bilirubin (mg/dL) | 0.70 (0.3–3.1, 0.30) | 0.80 (0.40–1.7, 0.40) | 0.285 |
| ≥ 1.1/ < 1.1 | 29/131 | 19/85 | 0.976 |
| Aspartate transaminase (IU/L) | 28 (13–155, 18) | 35 (9–104, 26) | |
| ≥ 31/ < 31 | 67/93 | 62/42 | |
| Albumin (g/dL) | 4.1 (3.0–5.0, 0.40) | 3.9 (2.3–4.9, 0.50) | |
| ≥ 3.9/ < 3.9 | 122/38 | 58/46 | |
| Prothrombin activity (%) | 100 ± 17 | 92 ± 15 | |
| ≥ 69/ < 69 | 154/6 | 100/4 | 0.605 |
| Activated partial thromboplastin time (%) | 91 (24–140, 30) | 81 (46–140, 24) | |
| ≥ 69/ < 69 | 131/29 | 84/20 | 0.821 |
| Hemoglobin (g/dL) | 13 ± 2.2 | 13 ± 1.8 | |
| ≥ 11.4/ < 11.4 | 136/24 | 75/29 | |
| Platelet (× 104/μL) | 18.1 (3.20–61.8 | 16.4 (4.80–49.9, 8.60) | 0.185 |
| ≥ 15.3/ < 15.3 | 102/58 | 65/39 | 0.837 |
| Blood urea nitrogen (mg/dL) | 14.9 (7.00–39.5, 5.60) | 14.6 (7.00–27.2, 6.40) | 0.423 |
| ≥ | 24/136 | 16/88 | 0.932 |
| Creatinine (mg/dL) | 0.78 (0.35–5.50, 0.30) | 0.75 (0.43–2.30, 0.28) | 0.427 |
| ≥ | 21/139 | 12/92 | 0.703 |
| C-reactive proteinc (mg/dL) | 0.10 (0.00–9.80, 0.18) | 0.11 (0.01–24.2, 0.28) | 0.439 |
| ≥ 0.14/ < 0.14 | 61/93 | 35/44 | 0.491 |
| ICGR15d (%) | 15 (1–51, 10) | 11 (1–45, 10) | |
| ≥ 10/ < 10 | 116/37 | 54/45 | |
| Child–Pugh score | 5 (5–6, 0) | 5 (5–8, 0) | 0.352 |
Continuous data are presented as median (range, interquartile range) or mean ± standard deviation, whereas categorical data are shown as number of patients. Significant P values are in boldface
BMI, body mass index; ASA, American Society of Anesthesiologists; HCC, hepatocellular carcinoma; CCC, cholangiocellular carcinoma; meta, liver metastasis; HCV, hepatitis C virus; HBV, hepatitis B virus; ASH, alcoholic steatohepatitis; NASH, non-alcoholic steatohepatitis; ICGR15, indocyanine green retention rate at 15 min
aData on liver fibrosis were partially lacking (monopolar, 113 cases; bipolar, 84 cases)
bData on the size of the largest nodule and number of nodules were partially lacking because biliary tract cancer and benign disease could not be accurately measured (monopolar, 133 cases; bipolar, 97 cases)
cData on C-reactive protein were partially lacking (monopolar, 154 cases; bipolar, 79 cases)
dData on ICGR15 were partially lacking (monopolar, 153 cases; bipolar, 99 cases)
Patient characteristics after propensity score matching
| Monopolar (n = 73) | Bipolar (n = 73) | ||
|---|---|---|---|
| Age | 70 (31–87, 13) | 69 (38–85, 16) | 0.994 |
| Sex (male/female) | 52/21 | 51/22 | 0.856 |
| BMI | 22.2 (15.4–32.2, 4.20) | 22.8 (15.9–37.1, 4.50) | 0.768 |
| ASA (1/2/3) | 5/56/12 | 9/54/10 | 0.506 |
| Diagnosis (HCC/CCC/meta/biliary tract cancer/benign disease/other) | 41/7/15/2/8/0 | 46/4/15/3/5/0 | 0.246 |
| Background liver disease (normal/HCV/HBV/ASH/NASH/other) | 35/22/6/3/4/3 | 30/28/8/2/3/2 | 0.475 |
| Liver fibrosisa (f0–1, f2–4) | 29/33 | 23/38 | 0.309 |
| Type of resection (partial/lateral/subsegmentectomy/segmentectomy/hemihepatectectomy/trisegmentectomy) | 17/1/25/10/20/0 | 18/1/25/10/19/0 | 0.433 |
| Number of resected lesions | 1 (1–16, 0) | 1 (1–3, 0) | 0.365 |
| Size of the largest nodule on preoperative imagingb (cm) | 2.7 (0.9–20, 3.0) | 2.4 (0.5–10, 1.9) | 0.147 |
| Number of nodules on preoperative imagingb | 1 (1–10, 0) | 1 (1–10, 1) | 0.513 |
| Lymph node dissection (yes/no) | 11/62 | 9/64 | 0.630 |
| Biliary reconstruction (yes/no) | 5/68 | 6/67 | 0.754 |
| Intraoperative drain insert (yes/no) | 73/0 | 72/1 | 0.500 |
| Duration of drain placement | 4 (0–131, 4) | 5 (2–94, 3) | 0.112 |
| Neoadjuvant chemotherapy (yes/no/previous) | 10/62/1 | 11/60/2 | 0.584 |
| Total bilirubin (mg/dL) (≥ 1.1/ < 1.1) | 16/57 | 17/56 | 0.843 |
| Aspartate transaminase (IU/L) (≥ 31/ < 31) | 36/37 | 38/35 | 0.741 |
| Albumin (g/dL) (≥ 3.9/ < 3.9) | 26/47 | 26/47 | 1.000 |
| Prothrombin activity (%) (≥ 69/ < 69) | 69/4 | 71/2 | 0.340 |
| Activated partial thromboplastin time (%) (≥ 69/ < 69) | 62/11 | 65/8 | 0.461 |
| Hemoglobin (g/dL) (≥ 11.4/ < 11.4) | 58/15 | 59/14 | 0.836 |
| Platelet (× 104/μL) (≥ 15.3/ < 15.3) | 45/28 | 43/30 | 0.735 |
| Blood urea nitrogen (mg/dL) (≥ 20.0/ < 20.0) | 11/62 | 10/63 | 0.814 |
| Creatinine (mg/dL) (≥ 1.07/ < 1.07) | 14/59 | 9/64 | 0.256 |
| C-reactive proteinc (mg/dL) (≥ 0.14/ < 0.14) | 28/43 | 22/35 | 0.923 |
| ICGR15d (%) (≥ 10/ < 10) | 45/25 | 45/25 | 0.557 |
| Child–Pugh score | 5 (5–6, 0) | 5 (5–8, 0) | 0.084 |
Continuous data are presented as median (range, interquartile range), whereas categorical data are shown as number of patients
BMI, body mass index; ASA, American Society of Anesthesiologists; HCC, hepatocellular carcinoma; CCC, cholangiocellular carcinoma; meta, liver metastasis; HCV, hepatitis C virus; HBV, hepatitis B virus; ASH, alcoholic steatohepatitis; NASH, non-alcoholic steatohepatitis; ICGR15, indocyanine green retention rate at 15 min
aData on liver fibrosis were partially lacking (monopolar, 62 cases; bipolar, 61 cases)
bData on the size of the largest nodule and number of nodules were partially lacking because biliary tract cancer and benign disease could not be accurately measured (monopolar, 66 cases; bipolar, 68 cases)
cData on C-reactive protein were partially lacking (monopolar, 71 cases; bipolar, 57 cases)
dData on ICGR15 were partially lacking (monopolar, 70 cases; bipolar, 70 cases)
Intraoperative outcomes
| Monopolar (n = 73) | Bipolar (n = 73) | ||
|---|---|---|---|
| Total operative time (min) | 239 (74–673, 130) | 275 (89–562, 115) | |
| Transection timea (min) | 76 (15–298, 61) | 90 (20–240, 67) | 0.104 |
| Pringle maneuverb (min) | 54 (15–158, 30) | 66 (18–159, 35) | 0.101 |
| Blood loss (mL) | 487 (0–3275, 480) | 790 (145–8030, 832) | |
| Red blood cell transfusion (mL) | 0 (0–1120, 0) | 0 (0–3360, 320) |
Continuous data are presented as median (range, interquartile range). P values were calculated using the Mann–Whitney U test. Significant P values are in boldface
aData on total transection time were partially lacking (monopolar, 58 cases; bipolar, 67 cases)
bData on total Pringle maneuver time were partially lacking (monopolar, 46 cases; bipolar, 53 cases)
Linear mixed-effects model analysis between hemostatic device and postoperative day for each parameter
| Monopolar | Bipolar | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Parameter | Average | SE | 95% CI | Average | SE | 95% CI | |||
| Aspartate transaminase | 298 | 21 | 257, 339 | 167 | 20.8 | 125, 208 | |||
| C-reactive protein | 5.8 | 0.30 | 5.1, 6.4 | 6.0 | 0.3 | 5.3, 6.6 | 0.602 | ||
| Albumin | 2.9 | 0.04 | 2.8, 3.0 | 3.0 | 0.04 | 3.0, 3.1 | 0.135 | ||
P values were calculated using the linear mixed-effects model for repeated measures. Significant P values are in boldface
SE, standard error; CI, confidence interval
aP value between hemostatic devices
bP value between postoperative days
cP value between hemostatic device and postoperative day
Fig. 3Postoperative blood examination. Postoperative blood examinations are shown as a black line for the monopolar group and a dotted black line for the bipolar group. Error bars indicate standard error. Asterisks indicate significance (*P < 0.05)
Postoperative aspartate transaminase course
| Average | SE | 95% CI | |
|---|---|---|---|
| Day 1 | 546.4 | 21.9 | 503.4, 589.3 |
| Day 2 | 360.1 | 22.4 | 316.0, 404.1 |
| Day 3 | 158.9 | 27.4 | 105.1, 212.6 |
| Day 5 | 53.1 | 26.3 | 1.4, 104.7 |
| Day 7 | 42.6 | 22.3 | − 1.1, 86.4 |
SE, standard error; CI, confidence interval
Postoperative outcomes
| Monopolar (n = 73) | Bipolar (n = 73) | ||
|---|---|---|---|
| Operative mortality (yes/no) | 3/70 | 0/73 | 0.122 |
| Operative morbidity (yes/no) | 46/27 | 35/38 | 0.067 |
| Grade ≥ 3 operative morbidity (yes/no) | 18/55 | 10/63 | 0.093 |
| Pleural effusion (yes/no) | 8/65 | 15/58 | 0.112 |
| Grade ≥ 3 pleural effusion (yes/no) | 0/73 | 0/73 | – |
| Ascites (yes/no) | 20/53 | 6/67 | |
| Grade ≥ 3 ascites (yes/no) | 1/72 | 0/73 | 0.500 |
| Biliary leak (yes/no) | 6/67 | 6/67 | 1.000 |
| Grade ≥ 3 biliary leak (yes/no) | 6/67 | 6/67 | 1.000 |
| Pneumonia (yes/no) | 5/68 | 1/72 | 0.104 |
| Grade ≥ 3 pneumonia (yes/no) | 2/71 | 0/73 | 0.250 |
| Intra-abdominal infection (yes/no) | 10/63 | 6/67 | 0.289 |
| Grade ≥ 3 intra-abdominal infection (yes/no) | 9/64 | 2/71 | |
| Surgical site infection (yes/no) | 11/62 | 14/59 | 0.510 |
| Grade ≥ 3 surgical site infection (yes/no) | 1/72 | 2/71 | 0.500 |
| Liver failure (yes/no) | 4/69 | 0/73 | 0.060 |
| Grade ≥ 3 liver failure (yes/no) | 3/70 | 0/73 | 0.122 |
| CCI score | 8.70 (0.00–100, 26.2) | 0.00 (0.00–52.4, 20.9) | |
| Hospital stay (days) | 16 (4–93, 18) | 15 (8–99, 9) | 0.370 |
Continuous data are presented as median (range, interquartile range), whereas categorical data are shown as number of patients. P-values were calculated using Pearson’s chi-square test or Fisher’s exact test or the Mann–Whitney U test when appropriate. Significant P-values are in boldface
CCI, comprehensive complication index
Univariate and multivariate analyses for predicting ascites
| Variables | Ascites | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| Yes (n = 26) | No (n = 120) | OR | 95% CI | |||
| Age | 70 (31–79, 13) | 69 (33–87, 15) | 0.276 | |||
| Sex (male/female) | 19/7 | 84/36 | 0.755 | |||
| BMI | 21.3 (18.3–26.9, 4.5) | 22.9 (15.4–37.1, 4.5) | 0.162 | |||
| ASA (1 or 2/3) | 20/6 | 104/16 | 0.214 | |||
| Diagnosis (HCC/non-HCC) | 22/4 | 65/55 | 3.442 | 0.751–15.768 | 0.111 | |
| Background liver condition (hepatitis/normal) | 21/5 | 60/60 | 1.246 | 0.292–5.328 | 0.766 | |
| Type of resection (major hepatectomya/minor hepatectomyb) | 19/7 | 90/30 | 0.838 | |||
| Number of resected lesions | 1 (1–3, 1) | 1 (1–16, 0) | 0.979 | |||
| Size of the largest nodule on preoperative imagingc (cm) | 2.3 (0.9–20.0, 2.7) | 2.5 (0.5–12.0, 2.0) | 0.582 | |||
| Number of nodules on preoperative imagingc | 1 (1–10, 2) | 1 (1–10, 0) | 0.204 | |||
| Lymph node dissection (yes/no) | 3/23 | 17/103 | 0.724 | |||
| Biliary reconstruction (yes/no) | 1/25 | 10/110 | 0.444 | |||
| Neoadjuvant chemotherapy (yes/no or previous) | 2/24 | 19/101 | 0.295 | |||
| Total bilirubin (mg/dL) (≥ 1.1/ < 1.1) | 8/18 | 25/95 | 0.276 | |||
| Aspartate transaminase (IU/L) (≥ 31/ < 31) | 16/10 | 58/62 | 0.225 | |||
| Albumin (g/dL) (≥ 3.9/ < 3.9) | 13/13 | 81/39 | 0.095 | |||
| Prothrombin activity (%) (≥ 69/ < 69) | 22/4 | 118/2 | 0.275 | 0.032–2.330 | 0.236 | |
| Activated partial thromboplastin time (%) (≥ 69/ < 69) | 22/4 | 105/15 | 0.692 | |||
| Hemoglobin (g/dL) (≥ 11.4/ < 11.4) | 21/5 | 96/24 | 0.929 | |||
| Platelet (× 104/μL) (≥ 15.3/ < 15.3) | 8/18 | 80/40 | 0.359 | 0.123–1.050 | 0.061 | |
| Blood urea nitrogen (mg/dL) (≥ 20.0/ < 20.0) | 5/21 | 16/104 | 0.440 | |||
| Creatinine (mg/dL) (≥ 1.07/ < 1.07) | 3/23 | 20/100 | 0.518 | |||
| C-reactive proteind (mg/dL) (≥ 0.14/ < 0.14) | 10/15 | 40/63 | 0.915 | |||
| ICGR15e (%) (≥ 10/ < 10) | 19/7 | 71/43 | 0.588 | |||
| Child–Pugh score | 5 (5–6, 1) | 5 (5–8, 0) | 0.509 | 0.191–1.354 | 0.176 | |
| Total operative time (min) | 257 (123–673, 167) | 253 (74–670, 115) | 0.397 | |||
| Transection timef (min) | 96 (19–262, 77) | 84 (15–298, 63) | 0.682 | |||
| Pringle maneuverg (min) | 54 (18–158, 51) | 58 (15–159, 31) | 0.962 | |||
| Blood loss (mL) | 565 (35–8030, 997) | 550 (0–5940, 629) | 0.269 | |||
| Red blood cell transfusion (mL) | 0 (0–3360, 90) | 0 (0–2850, 0) | 0.218 | |||
| Hemostatic device (monopolar/bipolar) | 20/6 | 53/67 | 5.626 | 1.881–16.827 | ||
Continuous data are presented as median (range, interquartile range), whereas categorical data are shown as number of patients. Significant P-values are in boldface
BMI, body mass index; ASA, American Society of Anesthesiologists; HCC, hepatocellular carcinoma; ICGR15, indocyanine green retention rate at 15 min; OR, odds ratio; CI, confidence interval
aMajor hepatectomy indicates more than one section hepatectomy excluding left lateral hepatectomy
bMinor hepatectomy indicates partial and left lateral hepatectomy
cData on the size of the largest nodule and number of nodules were partially lacking because biliary tract cancer and benign disease could not be accurately measured (with ascites, 24 cases; without ascites, 110 cases)
dData on C-reactive protein were partially lacking (with ascites, 25 cases; without ascites, 103 cases)
eData on ICGR15 were partially lacking (with ascites, 26 cases; without ascites, 114 cases)
fData on total transection time were partially lacking (with ascites, 21 cases; without ascites, 105 cases)
gData on total Pringle maneuver time were partially lacking (with ascites, 19 cases; without ascites, 80 cases)
Univariate and multivariate analyses for predicting grade ≥ 3 intra-abdominal infection
| Variables | Grade ≥ 3 intra-abdominal infection | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| Yes (n = 11) | No (n = 135) | OR | 95% CI | |||
| Age | 68 (37–84, 12) | 70 (31–87, 15) | 0.439 | |||
| Sex (male/female) | 9/2 | 94/41 | 0.402 | |||
| BMI | 24.7 (18.8–27.3, 7.4) | 22.4 (15.4–37.1, 4.2) | 0.368 | |||
| ASA (1 or 2/3) | 10/1 | 114/21 | 0.570 | |||
| Diagnosis (HCC/non-HCC) | 4/7 | 83/52 | 0.115 | |||
| Background liver condition (hepatitis/normal) | 4/7 | 77/58 | 0.195 | |||
| Type of resection (major hepatectomya/minor hepatectomyb) | 10/1 | 99/36 | 0.226 | |||
| Number of resected lesions | 1 (1–2, 0) | 1 (1–16, 0) | 0.494 | |||
| Size of the largest nodule on preoperative imagingc (cm) | 2.3 (1.2–5.0, 2.1) | 2.5 (0.5–20.0, 2.1) | 0.435 | |||
| Number of nodules on preoperative imagingc | 1 (1–10, 1) | 1 (1–10, 1) | 0.577 | |||
| Lymph node dissection (yes/no) | 5/6 | 15/120 | 8.661 | 1.985–37.794 | ||
| Biliary reconstruction (yes/no) | 2/9 | 9/126 | 0.184 | |||
| Neoadjuvant chemotherapy (yes/no or previous) | 2/9 | 19/116 | 0.710 | |||
| Total bilirubin (mg/dL) (≥ 1.1/ < 1.1) | 3/8 | 30/105 | 0.701 | |||
| Aspartate transaminase (IU/L) (≥ 31/ < 31) | 2/9 | 72/63 | 0.151 | 0.028–0.823 | ||
| Albumin (g/dL) (≥ 3.9/ < 3.9) | 9/2 | 85/50 | 0.225 | |||
| Prothrombin activity (%) (≥ 69/ < 69) | 11/0 | 129/6 | 0.999 | |||
| Activated partial thromboplastin time (%) (≥ 69/ < 69) | 8/3 | 119/16 | 0.159 | |||
| Hemoglobin (g/dL) (≥ 11.4/ < 11.4) | 10/1 | 107/28 | 0.369 | |||
| Platelet (× 104/μL) (≥ 15.3/ < 15.3) | 9/2 | 79/56 | 0.148 | |||
| Blood urea nitrogen (mg/dL) (≥ 20.0/ < 20.0) | 1/10 | 20/115 | 0.607 | |||
| Creatinine (mg/dL) (≥ 1.07/ < 1.07) | 2/9 | 21/114 | 0.818 | |||
| C-reactive proteind (mg/dL) (≥ 0.14/ < 0.14) | 2/9 | 48/69 | 0.156 | |||
| ICGR15e (%) (≥ 10/ < 10) | 4/6 | 86/44 | 0.213 | |||
| Child–Pugh score | 5 (5–5, 0) | 5 (5–8, 0) | 0.998 | |||
| Total operative time (min) | 318 (202–438, 167) | 251 (74–673, 119) | 0.244 | |||
| Transection timef (min) | 89 (50–223, 63) | 84 (15–298, 67) | 0.494 | |||
| Pringle maneuverg (min) | 61 (41–119, 50) | 56 (15–159, 32) | 0.286 | |||
| Blood loss (mL) | 470 (120–1365, 425) | 565 (0–8030, 676) | 0.321 | |||
| Red blood cell transfusion (mL) | 0 (0–0, 0) | 0 (0–3360, 0) | 0.996 | |||
| Hemostatic device (monopolar/bipolar) | 9/2 | 64/71 | 5.905 | 1.096–31.825 | ||
Continuous data are presented as median (range, interquartile range), whereas categorical data are shown as number of patients. Significant P-values are in boldface
BMI, body mass index; ASA, American Society of Anesthesiologists; HCC, hepatocellular carcinoma; ICGR15, indocyanine green retention rate at 15 min; OR, odds ratio; CI, confidence interval
aMajor hepatectomy indicates more than one section hepatectomy excluding left lateral hepatectomy
bMinor hepatectomy indicates partial and left lateral hepatectomy
cData on the size of the largest nodule and number of nodules were partially lacking because biliary tract cancer and benign disease could not be accurately measured (with ascites, 8 cases; without ascites, 126 cases)
dData on C-reactive protein were partially lacking (with ascites, 11 cases; without ascites, 117 cases)
eData on ICGR15 were partially lacking (with ascites, 10 cases; without ascites, 130 cases)
fData on total transection time were partially lacking (with ascites, 11 cases; without ascites, 115 cases)
gData on total Pringle maneuver time were partially lacking (with ascites, 9 cases; without ascites, 90 cases)
Fig. 4Histopathological examination of thermal damage to the resected specimens. a Macroscopic findings revealed that the burned area was divided into two areas from a “white zone” to a “gray zone.” The area between the “gray zone” and tumors was recognized as the “normal zone.” The measurement of the burned area is shown with the black line. b Illustration of macroscopic findings. c The black dotted line indicates the border between the “white zone” and “gray zone.” Scale bar: 1 mm. d Hepatocellular degeneration, dilatation of the sinusoidal space, crush degeneration of Glisson’s sheath, hemorrhage, and hyperemia were observed in the “white zone.” Scale bar: 250 μm. e Thermal damage length in the resected specimens caused by hemostatic devices. Horizontal lines denote median values; boxes denote the interquartile range; whiskers denote minimum and maximum values. f Incidence rate of ascites. g Incidence rate of intra-abdominal abscess. Asterisks indicate significance (*P < 0.05)